Viking Therapeutics Completes Enrollment for VK2735 Obesity Maintenance Dosing Study

Reuters01-08

<a href="https://laohu8.com/S/VKTX">Viking</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Completes Enrollment for VK2735 Obesity Maintenance Dosing Study

Viking Therapeutics Inc. announced the completion of patient enrollment in its exploratory maintenance dosing clinical trial of VK2735 for obesity. VK2735 is a dual agonist of the GLP-1 and GIP receptors, being developed in both oral and subcutaneous formulations for the treatment of metabolic disorders such as obesity. The Phase 1 study is evaluating various maintenance dosing regimens—including subcutaneous and oral administration—following initial weight loss achieved with weekly VK2735 treatment. Approximately 180 adults with obesity have been enrolled. Results from this study are expected to be reported later this year. In addition, Viking is conducting two Phase 3 trials (VANQUISH-1 and VANQUISH-2) to assess the efficacy and safety of subcutaneous VK2735 in adults with obesity or overweight, with or without type 2 diabetes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA58978) on January 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601366472?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601366472","market":"nz","top_or_hot":-1,"title":"Viking Therapeutics Completes Enrollment for VK2735 Obesity Maintenance Dosing Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VKTX\">Viking</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Completes Enrollment for VK2735 Obesity Maintenance Dosing Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Viking Therapeutics Inc. announced the completion of patient enrollment in its exploratory maintenance dosing clinical trial of VK2735 for obesity. VK2735 is a dual agonist of the GLP-1 and GIP receptors, being developed in both oral and subcutaneous formulations for the treatment of metabolic disorders such as obesity. The Phase 1 study is evaluating various maintenance dosing regimens—including subcutaneous and oral administration—following initial weight loss achieved with weekly VK2735 treatment. Approximately 180 adults with obesity have been enrolled. Results from this study are expected to be reported later this year. In addition, Viking is conducting two Phase 3 trials (VANQUISH-1 and VANQUISH-2) to assess the efficacy and safety of subcutaneous VK2735 in adults with obesity or overweight, with or without type 2 diabetes.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA58978) on January 08, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viking Therapeutics Completes Enrollment for VK2735 Obesity Maintenance Dosing Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViking Therapeutics Completes Enrollment for VK2735 Obesity Maintenance Dosing Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-08 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VKTX\">Viking</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Completes Enrollment for VK2735 Obesity Maintenance Dosing Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Viking Therapeutics Inc. announced the completion of patient enrollment in its exploratory maintenance dosing clinical trial of VK2735 for obesity. VK2735 is a dual agonist of the GLP-1 and GIP receptors, being developed in both oral and subcutaneous formulations for the treatment of metabolic disorders such as obesity. The Phase 1 study is evaluating various maintenance dosing regimens—including subcutaneous and oral administration—following initial weight loss achieved with weekly VK2735 treatment. Approximately 180 adults with obesity have been enrolled. Results from this study are expected to be reported later this year. In addition, Viking is conducting two Phase 3 trials (VANQUISH-1 and VANQUISH-2) to assess the efficacy and safety of subcutaneous VK2735 in adults with obesity or overweight, with or without type 2 diabetes.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA58978) on January 08, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4599","symbol_name":"减肥药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL7lNvG2:1","article_id":"2601366472","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601366472","pubTimestamp":1767873698,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Viking Therapeutics Inc. announced the completion of patient enrollment in its exploratory maintenance dosing clinical trial of VK2735 for obesity. VK2735 is a dual agonist of the GLP-1 and GIP receptors, being developed in both oral and subcutaneous formulations for the treatment of metabolic disorders such as obesity. The Phase 1 study is evaluating various maintenance dosing regimens—including subcutaneous and oral administration—following initial weight loss achieved with weekly VK2735 treatment. Approximately 180 adults with obesity have been enrolled. Results from this study are expected to be reported later this year. In addition, Viking is conducting two Phase 3 trials  to assess the efficacy and safety of subcutaneous VK2735 in adults with obesity or overweight, with or without type 2 diabetes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4599":"减肥药","BK4588":"碎股","VKTX":"Viking Therapeutics, Inc.","BK4139":"生物科技","BK4585":"ETF&股票定投概念"},"translate_title":"Viking Therapeutics完成VK2735肥胖维持给药研究的招募","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":0.9},"content_text":"Viking Therapeutics Completes Enrollment for VK2735 Obesity Maintenance Dosing Study\n    \n\n        Viking Therapeutics Inc. announced the completion of patient enrollment in its exploratory maintenance dosing clinical trial of VK2735 for obesity. VK2735 is a dual agonist of the GLP-1 and GIP receptors, being developed in both oral and subcutaneous formulations for the treatment of metabolic disorders such as obesity. The Phase 1 study is evaluating various maintenance dosing regimens—including subcutaneous and oral administration—following initial weight loss achieved with weekly VK2735 treatment. Approximately 180 adults with obesity have been enrolled. Results from this study are expected to be reported later this year. In addition, Viking is conducting two Phase 3 trials (VANQUISH-1 and VANQUISH-2) to assess the efficacy and safety of subcutaneous VK2735 in adults with obesity or overweight, with or without type 2 diabetes.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA58978) on January 08, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601366472","isCrawlerRequest":true}